Results failed to show the benefit of GLP-1 receptor agonists in reducing the risk of heart failure; in the LEADER, REWIND, EXSCEL, ELIXA and SUSTAIN-6 trials were no significant difference in HF hospitalization between GLP-1 receptor agonist and placebo group (37–44, 66). This evidence concerns the gene GLP1R and hydrops fetalis.